This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The present moment within and without healthcare, biotech, and pharma is a difficult and pivotal time in history, a time in which such issues need must be addressed. In order to do this, an EU network is in the process of being established between national comprehensive cancer centres and anticipated to be properly in place by 2025.
Reading time: 4 minutes A patient support network isn’t made up of just doctors or nurses. Our custom system was built in 2003,” said Brochhagen. VMS BioMarketing strives to make real, personal connections that help patients engage in their treatment regimen.
When we launched Mayo Clinic’s social media network and podcast, I used what I like to call the ‘proceed until apprehended’ model of innovation. And so that's why we created what we then called the Mayo clinic social media network Lee Aase: as a way to kind of monetize our leadership in a sense, but also to do the things we wanted to do like.
Bingham replied that pharma, biotech, and academia all need to come up with new approaches. However, she continued, pharma generally doesn’t voluntarily go down such a route. There were screening recommendations back in 2003 and they have yet to be fully implemented. These, after all, are expensive, she said.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content